HNF4A Antibody

What is HNF4A and what role does it play in cellular biology?

HNF4A (Hepatocyte nuclear factor 4 alpha) is a highly conserved transcription factor that functions as a master regulator in liver development and homeostasis. It plays crucial roles in cell fate determination, particularly in the specification of hepatic progenitor cells by regulating a network of transcription factors that control hepatocyte cell fate . HNF4A is essential for maintaining the active epigenetic state at enhancers in hepatocytes and protecting against various pathological conditions including colitis and liver fibrosis . The protein has a calculated molecular weight of 53 kDa, though it is typically observed at approximately 52 kDa in experimental contexts . HNF4A primarily binds to intronic (47.35%) and distal intergenic regions (33.33%), with a smaller proportion (9.81%) binding at gene promoters .

What are the recommended applications for HNF4A antibodies?

HNF4A antibodies have been validated for multiple experimental applications with specific recommended dilutions:

For optimal results, it is strongly recommended that researchers titrate the antibody concentration in each specific testing system, as performance can be sample-dependent . Published literature demonstrates successful application of HNF4A antibodies in Western blot and immunofluorescence studies investigating its role in epigenetic regulation and cellular differentiation .

What positive controls should be used when working with HNF4A antibodies?

Based on validation data, the following samples serve as reliable positive controls for HNF4A antibody experiments:

When performing immunohistochemistry, antigen retrieval is crucial for optimal results. The recommended protocol suggests using TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative . For immunofluorescence experiments, validated protocols are available from manufacturers and should be followed for consistent results .

How can researchers distinguish between different HNF4A isoforms experimentally?

HNF4A exists in multiple isoforms derived from alternative promoters (P1 and P2). Transcript variant 2 (NCBI: NM_000457.6) is the predominant variant in many cell lines, giving rise to the P1-derived HNF4-alpha-1 protein (UniprotKB: P41235-1) . To distinguish between these isoforms, researchers should:

• Design RT-qPCR primers specific to P1 and P2 transcript regions

• Use antibodies that can differentiate between isoforms (some antibodies recognize both embryonic and adult isoforms)

• Consider that P2-derived transcripts are typically less abundant than P1 transcripts in many cell types

Research has shown that under inflammatory conditions (e.g., LPS treatment in dHepaRG cells or cytokine treatment in HepG2 cells), P1 pre-mRNA levels can drop to approximately 10% after just 1 hour, while P2 transcript levels remain relatively stable . This differential regulation provides a mechanism to experimentally distinguish the isoforms.

What are the key methodological considerations for optimizing HNF4A immunostaining procedures?

Achieving high-quality immunostaining for HNF4A requires careful attention to several methodological factors:

• Antigen retrieval: For IHC applications, TE buffer at pH 9.0 is the preferred method, with citrate buffer at pH 6.0 as an alternative

• Antibody dilution optimization: Titration between 1:600-1:2400 for IHC and 1:50-1:500 for IF is recommended

• Fixation considerations: Standard 4% paraformaldehyde fixation works well for most applications

• Cell type selection: HepG2 cells serve as excellent positive controls for both WB and IF applications

• Incubation conditions: Follow specific protocols provided by antibody manufacturers for optimal temperature and duration

• Signal amplification: For low-abundance detection, consider signal amplification systems compatible with the detection method

The specific antibody selected (polyclonal versus recombinant) may require protocol adjustments. For instance, the polyclonal antibody 26245-1-AP has been validated for both WB and IHC applications, while the recombinant antibody 84316-7-RR is optimized for IF/ICC applications .

How does HNF4A contribute to the epigenetic landscape in hepatocytes?

HNF4A plays a critical role in shaping and maintaining the epigenetic landscape in hepatocytes through multiple mechanisms:

• Histone modification regulation: HNF4A is essential for maintaining active histone signatures, particularly H3K27ac, at its binding regions. In mice lacking HNF4A protein in hepatocytes, researchers observed a significant decrease in H3K27ac at regions normally bound by HNF4A .

• DNA methylation modulation: HNF4A binding sites are characterized by 5-hydroxymethylcytosine (5hmC) enrichment. HNF4A mediates the oxidation of 5-methylcytosine (5mC) to 5hmC during differentiation of hepatoblasts to hepatocytes through interaction with TET3, which has been identified as an HNF4A target gene in hepatoblasts .

• Enhancer activation: HNF4A predominantly binds to regions enriched for H3K4me1 and H3K27ac that also display DNaseI hypersensitivity, indicating its primary association with active enhancers . Analysis of HNF4A bound regions (HBRs) confirms features of active enhancers at genes like Cdc42bpb, Rfx4, Mgst3, and Ido2 .

• Cooperative and independent actions with FOXA2: Clustering analysis of HNF4A and FOXA2 binding reveals both overlapping and exclusive binding patterns. Regions exclusively bound by HNF4A (Cluster 1) show enrichment for H3K4me1, H3K27ac, and 5hmC while being depleted of 5mC compared to regions exclusively bound by FOXA2 (Cluster 5) .

These findings establish HNF4A as a master epigenetic regulator in hepatocytes, essential for establishing and maintaining active chromatin states at enhancers during liver development and homeostasis.

What experimental approaches can optimize ChIP-seq studies investigating HNF4A binding patterns?

Conducting successful ChIP-seq experiments for HNF4A requires specialized approaches to capture its binding patterns accurately:

• Antibody selection: Use antibodies validated specifically for ChIP applications that can recognize both embryonic and adult isoforms if comprehensive binding is desired

• Crosslinking optimization: Standard formaldehyde crosslinking (1%) for 10 minutes at room temperature works well for most HNF4A ChIP applications

• Sonication parameters: Optimize sonication conditions to generate DNA fragments between 200-500 bp for ideal resolution of binding sites

• Control selection: Include appropriate controls:

  • Input DNA (pre-immunoprecipitation)

  • IgG control (non-specific binding)

  • Biological replicates (minimum of 2-3)

• Data analysis approach:

  • Use K-means clustering (K=5 recommended) to identify distinct binding patterns

  • Tools like ChAsE have been successfully employed to analyze HNF4A binding clusters

  • Incorporate histone modification data (H3K4me1, H3K4me3, H3K27ac) for comprehensive binding site characterization

• Validation of ChIP-seq findings: Confirm selected binding sites using ChIP-qPCR with primers targeting specific regions of interest, such as the regulatory regions of Cdc42bpb, Rfx4, Mgst3, Ido2, and Tet3

When analyzing HNF4A binding patterns, researchers should note its preferential binding to intronic (47.35%) and distal intergenic regions (33.33%), with a smaller proportion at gene promoters (9.81%) . This distribution pattern is critical for proper interpretation of binding significance.

How can researchers investigate HNF4A's role in inflammatory response regulation?

HNF4A has been implicated in regulating inflammatory responses, particularly through its repression of acute-phase genes under basal conditions . To study this role, researchers can employ the following experimental strategies:

• Transcript monitoring: Track HNF4A P1 and P2 transcripts using RT-qPCR during inflammatory stimulation. Research has shown that in LPS-treated dHepaRG or cytokine-treated HepG2 cells, pre-mRNA of HNF4A P1 transcripts drop to 10% after just 1 hour of treatment .

• Inflammatory models:

  • In vitro: Treat HepG2 or dHepaRG cells with cytokines or LPS

  • In vivo: Chemical-induced colitis models or aged animal models for spontaneous colonic inflammation

• Binding site analysis: Investigate HNF4A binding near acute-phase genes. Studies have identified HNF4A binding peaks at 27 of 30 well-established acute-phase genes .

• Rescue experiments: After documenting reduced HNF4A expression during inflammation, perform viral vector-mediated HNF4A restoration to assess reversibility of inflammatory features .

• Conditional knockout models: Utilize epithelial-specific HNF4A knockout models to examine susceptibility to chemical-induced colitis and spontaneous colonic inflammation in aged animals .

This multifaceted approach allows researchers to comprehensively investigate HNF4A's complex regulatory role in inflammation, potentially revealing therapeutic targets for inflammatory conditions involving the liver and colon.

What methodological approaches can address the technical challenges in studying HNF4A-mediated DNA methylation changes?

Investigating HNF4A's influence on DNA methylation patterns presents several technical challenges that can be addressed through specialized methodological approaches:

• Integrated profiling approach: Combine multiple epigenetic profiling techniques to get a comprehensive view:

  • Methylated DNA immunoprecipitation (MeDIP) for 5mC analysis

  • Hydroxymethylated DNA immunoprecipitation (hMeDIP) for 5hmC analysis

  • ChIP-seq for histone modifications (particularly H3K4me1 and H3K27ac)

  • RNA-seq for gene expression correlation

• Validation of sequencing data: Confirm 5mC depletion and 5hmC enrichment at HNF4A binding regions using MeDIP- and hMeDIP-qPCR approaches. Include appropriate controls such as Dazl (positive), Tbx15 (negative), and IGd (no CpG) to validate your findings .

• TET3 interaction studies: Since HNF4A mediates DNA methylation changes through interaction with TET3:

  • Perform co-immunoprecipitation assays to confirm direct interaction

  • Use ChIP-reChIP to identify genomic regions bound by both proteins

  • Employ TET3 knockdown/knockout to assess its requirement for HNF4A-mediated 5hmC deposition

• Temporal analysis during differentiation: Track DNA methylation changes during hepatoblast-to-hepatocyte differentiation alongside HNF4A expression to establish causality rather than correlation .

• Bioinformatic integration: Develop computational pipelines to integrate DNA methylation, hydroxymethylation, and transcription factor binding data to identify direct targets of HNF4A-mediated epigenetic regulation.

By systematically addressing these technical challenges, researchers can establish more definitive connections between HNF4A binding and DNA methylation status, further illuminating its role as a master epigenetic regulator.

How can HNF4A antibodies be utilized to investigate potential therapeutic applications in liver fibrosis?

Liver fibrosis represents a significant clinical challenge, and HNF4A has emerged as a potential therapeutic target based on several key observations. Researchers can employ HNF4A antibodies to investigate therapeutic applications through:

• Expression profiling in fibrotic tissues: Use immunohistochemistry (IHC) with HNF4A antibodies (dilution 1:600-1:2400) to characterize expression patterns in normal versus fibrotic liver tissues. Research has documented reduced expression of HNF4A in liver fibrosis .

• Mechanistic studies: Employ western blotting to quantify HNF4A protein levels before and after potential therapeutic interventions. This allows for correlation between HNF4A restoration and phenotypic improvements.

• Target validation experiments:

  • Use viral vector-mediated HNF4A restoration in fibrotic models to assess reversal of pathological features

  • Document changes in downstream effectors and fibrosis markers following HNF4A restoration

  • Employ immunofluorescence to track cellular localization changes during disease progression and treatment

• Biomarker development: Validate HNF4A as a prognostic or predictive biomarker for fibrosis progression or treatment response using antibody-based detection methods.

Studies have demonstrated that viral vector-mediated HNF4A restoration can reverse features of chronic liver injury, supporting HNF4A as a therapeutic target for liver fibrosis treatment . Antibody-based techniques provide critical tools for monitoring expression, localization, and downstream effects in both experimental models and potential clinical applications.

What experimental considerations are important when using HNF4A antibodies in cancer research?

HNF4A has demonstrated tumor suppressor properties in hepatocellular carcinoma models, making it a subject of interest in cancer research . When using HNF4A antibodies for cancer studies, researchers should consider:

• Isoform specificity: Different HNF4A isoforms may have distinct roles in tumorigenesis. Ensure the selected antibody can distinguish relevant isoforms or complement with isoform-specific RT-qPCR.

• Microenvironment context: The tumor microenvironment may influence HNF4A expression and function. Use multiplex immunofluorescence to simultaneously visualize HNF4A with markers of inflammation, hypoxia, or cellular stress.

• Post-translational modifications: Cancer-associated alterations in post-translational modifications may affect antibody recognition. Consider phospho-specific antibodies if relevant to your research question.

• Heterogeneity considerations: Tumors exhibit significant heterogeneity. Use tissue microarrays and multiple tumor regions to capture expression patterns across different areas of the tumor.

• Functional validation: Complement antibody-based detection with functional assays that assess HNF4A's role in repressing cancer cell proliferation, a property documented in previous research .

• Clinical correlation: When studying human samples, correlate HNF4A expression patterns with clinical parameters including stage, grade, treatment response, and patient outcomes for translational relevance.

By addressing these considerations, researchers can generate more robust and clinically relevant data on HNF4A's role in cancer biology, potentially identifying new therapeutic strategies or biomarkers.

What emerging technologies might enhance HNF4A antibody-based research?

Several cutting-edge technologies show promise for advancing HNF4A antibody-based research:

• Single-cell applications: Adapting HNF4A antibodies for single-cell Western blotting or single-cell proteomics would enable analysis of expression heterogeneity at unprecedented resolution.

• Proximity labeling techniques: BioID or APEX2 fusions with HNF4A could identify previously unknown protein interaction partners in living cells, expanding our understanding of its regulatory network.

• Live-cell imaging: Development of non-interfering antibody fragments or nanobodies against HNF4A would permit visualization of its dynamics in living cells during differentiation or stress responses.

• Spatial transcriptomics integration: Combining immunostaining with spatial transcriptomics would allow correlation of HNF4A protein localization with gene expression patterns in intact tissue contexts.

• CRISPR-based epigenome editing: Targeted recruitment of epigenetic modifiers to HNF4A binding sites could help parse the causality in HNF4A-associated epigenetic changes .

These technological advances will likely provide deeper insights into HNF4A's multifaceted roles in development, homeostasis, and disease, potentially revealing new therapeutic targets and diagnostic approaches.

How can researchers contribute to standardizing HNF4A antibody validation procedures?

To improve reproducibility and reliability in HNF4A research, standardization of antibody validation procedures is essential. Researchers can contribute by:

• Implementing comprehensive validation protocols:

  • Testing in knockout/knockdown models to confirm specificity

  • Verifying recognition across multiple applications (WB, IHC, IF, ChIP)

  • Documenting batch variations through consistent quality control procedures

• Reporting detailed methodology: Include comprehensive methods sections in publications with specific antibody catalog numbers, dilutions, incubation conditions, and positive/negative controls used.

• Contributing to antibody validation repositories: Share validation data through platforms like Antibodypedia or the Antibody Registry to build a community knowledge base.

• Employing orthogonal validation: Confirm antibody-based findings using independent methods such as mass spectrometry or CRISPR-based tagging of endogenous proteins.

• Developing application-specific standards: Establish minimum validation requirements for specialized applications such as ChIP-seq or proximity ligation assays involving HNF4A.